BX471 hydrochloride is primarily utilized in research settings to study its effects on inflammatory processes. It acts as a selective antagonist for the CCR1 chemokine receptor, which plays a significant role in immune cell migration and inflammation. This compound is often employed in preclinical studies to investigate its potential in treating inflammatory and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and other conditions where CCR1 signaling is implicated. Additionally, it is used to explore its efficacy in reducing inflammation in various experimental models, helping researchers understand the underlying mechanisms of CCR1-mediated pathways. Its application extends to drug development, where it serves as a tool to identify and validate new therapeutic targets for inflammatory disorders.